Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163554 | 0.86 | MEN1 (0.44) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL689321 | 0.86 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL356816 | 0.84 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL8773482 | 0.84 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL5343307 | 0.84 | MEN1 (0.53) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL2694899 | 0.83 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL395409 | 0.83 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL67173 | 0.83 | RIPK1 (0.56) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL6105484 | 0.82 | MEN1 (0.48) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL6105491 | 0.82 | MEN1 (0.48) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304446-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-1408962-B1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-15 | — | — | EP | disclosed |
| EP-1408962-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003007942-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | MEN1 4632/4885KMT2A 4136/4885HTT 4548/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | MEN1 2172/4885KMT2A 4470/4885HTT 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.